| Name | Title | Contact Details |
|---|
PriorAuthNow`s powerful, secure software works with your EHR system and connects directly with all insurance carriers, making it the fastest, most economical way to submit, monitor and complete prior authorizations.
Ring`s research team has uncovered the world`s largest collection of commensal anelloviruses and are harnessing these natural viruses to target a wide array of diseases with significant unmet need. The unique biology of anelloviruses provides a foundation for a revolutionary new platform and a new class of programmable medicines.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company`s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point`s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to overcome treatment resistance common in other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Primorigen Biosciences LLC is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The KPC Group is a Riverside, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.